• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Lupin launches generic Tobramycin Inhalation Solution USP in US

financialexpressJune 14, 2018

Tag: lupin , generic Tobramycin , USP

Lupin has launched Tobramycin Inhalation Solution USP in the US market. The solution has received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).

Register as Visitor to CPhI China 2018!

Previous:Regenerative bandage accelerates healing in diabetic wounds

Next:Bayer to acquire stake in Monsanto India

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Lupin launches generic Tobramycin Inhalation Solution USP in US | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

盐酸异丙肾上腺素Isoprenaline Hydrochloride|CAS NO.:51-30-9|EP/USP|manufacturer

盐酸异丙肾上腺素Isoprenaline Hydrochloride|CAS NO.:51-30-9|EP/USP|manufacturer
Cabergoline USP/EP

Cabergoline USP/EP
Controlled release matrix formers, suspension aids

Controlled release matrix formers, suspension aids
Albendazole Oral Suspension 10%

Albendazole Oral Suspension 10%
Polygonum Cuspidatum Extract 50%-98% Emodin

Polygonum Cuspidatum Extract 50%-98% Emodin
Ciprofloxacin Tablet USP 500MG

Ciprofloxacin Tablet USP 500MG
Norethindrone ≥97.0% USP API Hormone made in china

Norethindrone ≥97.0% USP API Hormone made in china
Vitamin   B complex for suspension 

Vitamin   B complex for suspension 
COENZYME usp GMP China

COENZYME usp GMP China
99% up by HPLC USP GMP DMF Everolimus 159351-69-6

99% up by HPLC USP GMP DMF Everolimus 159351-69-6

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service